Quest Diagnostics

Quest Diagnostics P/B

The P/B (Price-to-Book Ratio) of Quest Diagnostics (DGX) as of Nov 20, 2026 is 3.21. In the previous year, P/B (Price-to-Book Ratio) was 3.40 — a change of -5.47% (lower).

P/B

3.21

YoY

-5.47%

Last updated:

P/B (Price-to-Book Ratio) of Quest Diagnostics is 2025 3.21 . P/B (Price-to-Book Ratio) of Quest Diagnostics was 2024 3.40 . It decreases by -5.47% lower compared to the previous year.

The Quest Diagnostics P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
4.41 USD
Jan 1, 2019
4.08 USD
Jan 1, 2020
3.40 USD
Jan 1, 2021
3.57 USD
Jan 1, 2022
3.91 USD
Jan 1, 2023
3.65 USD
Jan 1, 2024
3.40 USD
Jan 1, 2025
3.21 USD
The Quest Diagnostics P/B history
YEARP/BYoY
3.21-5.47%
3.40-6.95%
3.65-6.56%
3.91+9.35%
3.57+4.89%
3.40-16.54%
4.08-7.53%
4.41-5.66%
4.68-5.95%
4.97+1.21%
4.91-8.18%
5.35—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quest Diagnostics Stock analysis

What does Quest Diagnostics do? Quest Diagnostics Inc is a leading company in the field of diagnostic information and services, headquartered in New Jersey, USA. The company is dedicated to providing medical professionals and patients worldwide with fast, accurate, and preventive diagnostic tests. The history of Quest Diagnostics dates back to 1967 when the company MetPath was founded by Dr. Paul A. Brown. In the following years, several acquisitions and mergers took place, eventually leading to the establishment of Quest Diagnostics in 1996. Since then, the company has continuously evolved and now offers a wide range of diagnostic tests and services, ranging from the analysis of blood samples to genetic testing procedures. The business model of Quest Diagnostics is based on providing high-quality and individualized information to medical professionals and patients to assist in the diagnosis, treatment, and cure of their health problems. The company works closely with doctors, hospitals, and other medical institutions worldwide to offer a comprehensive range of innovative diagnostic products, procedures, and technologies tailored to meet specific needs. Quest Diagnostics offers a wide range of services, ranging from laboratory testing to data management and clinical trials. The company has various business segments, including the Diagnostic Services business, the Medical Research Services business, and the Information Services business. In the field of Diagnostic Services, Quest Diagnostics offers a broad spectrum of laboratory tests divided into different categories such as cancer diagnostics, cardiology, endocrinology, immunology, and infectious diseases. The company also provides a variety of genetic tests that enable precise analysis of individual genomes, supporting the diagnosis and treatment of various genetic disorders. In the medical research field, Quest Diagnostics provides a range of services to support clinical trials and drug development. The company also offers a wide range of laboratory tests used in biomedical research to improve people's health and well-being. The Information Services business segment of Quest Diagnostics mainly focuses on providing innovative solutions in the field of data management and information technology. This includes the development of software tools that can be used for the analysis and management of health data. Additionally, the company offers consulting services to help medical professionals address challenges related to information processing and data integration. Quest Diagnostics is a company based on innovation and knowledge that collaborates closely with doctors, clinics, and other medical facilities worldwide to offer a relatively comprehensive range of need-specific diagnostic products, procedures, and solutions. From cancer diagnostics to genomic diagnostics, from clinical trials to information and data services, and a wide range of molecular diagnostic tests and laboratory analyses, Quest Diagnostics provides top-notch solutions for optimal patient care, contributing to the goal of improving global healthcare for people worldwide. Quest Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quest Diagnostics stock

P/B (Price-to-Book Ratio) of Quest Diagnostics is 3.21 in 2025.

P/B (Price-to-Book Ratio) of Quest Diagnostics changed from 3.40 to 3.21, representing a -5.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Quest Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Quest Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Quest Diagnostics

All Key Metrics — Quest Diagnostics